Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
CASC's Cash-to-Debt is ranked higher than
100% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CASC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CASC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.63  Med: 161.9 Max: No Debt
Current: No Debt
Interest Coverage No Debt
CASC's Interest Coverage is ranked higher than
100% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CASC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CASC' s Interest Coverage Range Over the Past 10 Years
Min: 1060.29  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 17.04
Beneish M-Score: -3.02
WACC vs ROIC
18.39%
-311.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -62.49
CASC's ROE % is ranked lower than
72% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CASC: -62.49 )
Ranked among companies with meaningful ROE % only.
CASC' s ROE % Range Over the Past 10 Years
Min: -163.15  Med: -65.96 Max: 45.34
Current: -62.49
-163.15
45.34
ROA % -54.03
CASC's ROA % is ranked lower than
74% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CASC: -54.03 )
Ranked among companies with meaningful ROA % only.
CASC' s ROA % Range Over the Past 10 Years
Min: -80.5  Med: -50.43 Max: 24.26
Current: -54.03
-80.5
24.26
ROC (Joel Greenblatt) % -4107.43
CASC's ROC (Joel Greenblatt) % is ranked lower than
79% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CASC: -4107.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CASC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3993.53  Med: -2109.3 Max: 661.83
Current: -4107.43
-3993.53
661.83
3-Year EBITDA Growth Rate -5.20
CASC's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CASC: -5.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CASC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -60.2  Med: -9.5 Max: 91.8
Current: -5.2
-60.2
91.8
3-Year EPS without NRI Growth Rate -5.60
CASC's 3-Year EPS without NRI Growth Rate is ranked lower than
54% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CASC: -5.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CASC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57  Med: -11.4 Max: 28.8
Current: -5.6
-57
28.8
GuruFocus has detected 1 Warning Sign with Cascadian Therapeutics Inc $CASC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CASC's 30-Y Financials

Financials (Next Earnings Date: 2017-08-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

CASC Guru Trades in Q2 2016

Paul Tudor Jones 48,760 sh (New)
Seth Klarman 25,000,000 sh (New)
First Eagle Investment 400,000 sh (New)
» More
Q3 2016

CASC Guru Trades in Q3 2016

Seth Klarman 25,000,000 sh (unchged)
Paul Tudor Jones 48,760 sh (unchged)
First Eagle Investment 400,000 sh (unchged)
» More
Q4 2016

CASC Guru Trades in Q4 2016

Seth Klarman 4,166,666 sh (unchged)
Paul Tudor Jones Sold Out
First Eagle Investment 24,999 sh (-62.50%)
» More
Q1 2017

CASC Guru Trades in Q1 2017

Jim Simons 17,988 sh (New)
Seth Klarman 8,721,079 sh (+109.31%)
First Eagle Investment Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CASC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 8731
Compare:NAS:VRNA, NAS:CDXS, NAS:CORI, NAS:MNOV, NAS:IMDZ, NAS:CMRX, OTCPK:ELVAF, NAS:CEMP, NAS:STML, NAS:FBIO, NAS:KURA, NAS:ARDX, NAS:NYMX, NAS:URGN, NAS:TIG, OTCPK:PRMCF, NAS:ABEO, NAS:ENZY, NAS:MDGL, NAS:PIRS » details
Traded in other countries:3O61.Germany,
Headquarter Location:USA
Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing therapeutic product candidates for the treatment of cancer. Its product candidate is ONT-380, an orally active & selective small molecule HER2 inhibitor.

Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.

Top Ranked Articles about Cascadian Therapeutics Inc

Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for Today at 8:30 a.m. ET
Cascadian Therapeutics to Report First Quarter 2017 Financial Results on May 9, 2017
Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017
Cascadian Therapeutics Announces Changes to Board of Directors

SEATTLE, March 13, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Robert W. Azelby has been appointed to the Company’s Board of Directors. Mr. Azelby is a biotechnology and pharmaceutical industry veteran. He currently serves as Executive Vice President and Chief Commercial Officer of Juno Therapeutics. The Company also announced that Richard L. Jackson, Ph.D. retired from the Board as of March 8, 2017.
“I would like to thank Dr. Jackson for his years of service as a director and welcome Mr. Azelby to the team,” said Dr. Christopher S. Henney, Chairman of Cascadian Therapeutics’ Board of Directors. “Mr. Azelby’s background in product development, market access and commercial operations will provide a strong addition to our Board.” “I am delighted to join Cascadian Therapeutics’ Board of Directors and offering my experience at this pivotal time while the company advances tucatinib into late-stage development,” said Mr. Azelby. Robert Azelby has served as Chief Commercial Officer at Juno Therapeutics since November 2015. Prior to Juno, he was with Amgen for 15 years, serving most recently as Vice President and General Manager of Amgen’s $6 billion U.S. Oncology business. About Cascadian Therapeutics Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. The lead product candidate, tucatinib, is an oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo in combination with capecitabine and trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com. For more information, please visit www.cascadianrx.com
Forward-Looking Statements In order to provide Cascadian Therapeutics' investors with an understanding of its current results and future prospects, this release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include Cascadian Therapeutics' expectations regarding clinical development activities and potential benefits of tucatinib. Forward-looking statements involve risks and uncertainties related to Cascadian Therapeutics' business and the general economic environment, many of which are beyond its control. These risks, uncertainties and other factors could cause Cascadian Therapeutics' actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing its product candidates, the adequacy of financing and cash, cash equivalents and investments, changes in general accounting policies, general economic factors, achievement of the results it anticipates from its preclinical development and clinical trials of its product candidates and its ability to adequately obtain and protect its intellectual property rights. Although Cascadian Therapeutics believes that the forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of Cascadian Therapeutics' risks and uncertainties, you are encouraged to review the documents filed with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Except as required by law, Cascadian Therapeutics does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
Investor and Media Contact:
Monique Greer
Cascadian Therapeutics
206-801-2107
[email protected]

Read more...
Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
SEATTLE, March 09, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC) today reported financial results for the fourth quarter and full year ended December 31, 2016.
“In 2016, we focused our efforts on the development of tucatinib for late-stage HER2-positive metastatic breast cancer for patients with and without brain metastases and amended our ongoing HER2CLIMB study by increasing the sample size so that, if successful, the trial could serve as a single pivotal trial to support registration,” said Scott Myers, President and CEO of Cascadian Therapeutics. “For 2017, we have prioritized our resources on expanding HER2CLIMB globally and exploring the potential utility of tucatinib in additional HER2-positive expressing cancers. With a global development plan underway, clarity on a U.S. regulatory pathway and a solid financial position, we have set the foundation to execute our strategy.”Fourth Quarter and Recent HighlightsTucatinib – targeted HER2 inhibitorIn December 2016, researchers presented updated data from the Company’s ongoing Phase 1b Triplet combination study (tucatinib with capecitabine and trastuzumab) at the 2016 San Antonio Breast Cancer Symposium. This Triplet combination continued to be well tolerated and showed an updated median progression-free survival of 7.8 months, an overall response rate of 61 percent and a median duration of response of 10 months. Patients treated with the Triplet combination previously received a median of 3 HER2-targeted agents, such as trastuzumab, pertuzumab, lapatinib and T-DM1.

In December 2016, the Company announced that, following a meeting with the U.S. Food and Drug Administration (FDA) and discussions with the Company’s external Steering Committee, the Company amended the HER2CLIMB trial of tucatinib by increasing the sample size so that, if successful, the trial could serve as a single pivotal study to support a new drug application.

In October 2016, the Company announced presentation of data from the ongoing Phase 1b Triplet combination study (tucatinib with capecitabine and trastuzumab) at the European Society for Medical Oncology 2016 Congress that showed clinical activity in HER2-positive metastatic lesions to the skin.CASC-578 – a novel Chk1 cell cycle inhibitorIn December 2016, the Company completed a non-human pharmacology study to evaluate the impact of CASC-578 on multiple cardiovascular endpoints. The results indicate CASC-578 has an acceptable profile at the doses tested and warrants further study of the drug in both single agent and combination settings.CorporateIn January 2017, the Company strengthened its balance sheet through an underwritten public offering, resulting in net proceeds of approximately $88 million.Fourth Quarter and Full Year 2016 Financial ResultsCash, cash equivalents and investments totaled $62.8 million as of December 31, 2016, compared to $56.4 million at December 31, 2015, an increase of $6.4 million, or 11.3 percent. The increase was primarily due to the result of net proceeds of $43.3 million from the Company’s June 2016 financing offset by cash used to fund operations of $36.9 million.

Net loss attributable to common stockholders for the three months ended December 31, 2016 was $10.5 million, or $0.47 per share, compared to a net loss attributable to common stockholders of $9.1 million, or $0.58 per share, for the same period in 2015. The $1.4 million increase in net loss attributable to common stockholders for the quarter was primarily due to an increase in research and development expense associated with the development of the Company’s product candidates and an increase in general and administrative expense, which included expenses related to headcount and the Company’s adoption of the Retention Plan in early January 2016.

Net loss attributable to common stockholders for the year ended December 31, 2016 was $60.3 million, or $3.13 per share, compared to a net loss attributable to common stockholders of $32.6 million, or $2.02 per share, for the same period in 2015. The increase in net loss attributable to common stockholders for the year ended December 31, 2016 was primarily due to the intangible asset impairment charge of $19.7 million, which was the result of the mutual termination of the STC.UNM agreement. In addition, the increases in research and development expenses of $4.0 million, due to greater activity related to the development of the Company’s product candidates, and increases in general and administrative expenses of $8.3 million, primarily related to the retirement and separation of the former chief executive officer and other headcount-related expenses, contributed to the year-over-year increase in net loss. The Company also recognized a non-cash $2.6 million deemed dividend due to the beneficial conversion feature on the Series D convertible preferred stock. The increase in the net loss attributable to common stockholders was partially offset by a $6.9 million tax benefit during the year ended December 31, 2016.2017 Financial OutlookCascadian Therapeutics believes the following financial guidance to be correct as of the date provided and is providing the guidance as a convenience to investors and assumes no obligation to update it.Cascadian Therapeutics expects operating expenses in 2017 to be slightly higher than in 2016, which included a one-time expense associated with the intangible asset impairment. The 2017 increase is due to an increase in activities related to the ongoing HER2CLIMB pivotal trial. Cash used in operations is expected to be approximately $50.0 million to $54.0 million.
About Cascadian TherapeuticsCascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. The lead product candidate, tucatinib, is an oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo in combination with capecitabine and trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com. For more information, please visit www.cascadianrx.com.
Forward-Looking StatementsIn order to provide Cascadian Therapeutics' investors with an understanding of its current results and future prospects, this release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include Cascadian Therapeutics' expectations regarding clinical development activities, timing of additional data, potential benefits of its product candidates, and its use and adequacy of cash reserves and future financial results.Forward-looking statements involve risks and uncertainties related to Cascadian Therapeutics' business and the general economic environment, many of which are beyond its control. These risks, uncertainties and other factors could cause Cascadian Therapeutics' actual results to differ materially from those projected in forward-looking statements, including the risks associated with the costs and expenses of developing its product candidates, the adequacy of financing and cash, cash equivalents and investments, changes in general accounting policies, general economic factors, achievement of the results it anticipates from its preclinical development and clinical trials of its product candidates, the receipt of regulatory approvals, and its ability to adequately obtain and protect its intellectual property rights. Although Cascadian Therapeutics believes that the forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of Cascadian Therapeutics' risks and uncertainties, you are encouraged to review the documents filed with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Except as required by law, Cascadian Therapeutics does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.Additional Information
Additional information relating to Cascadian Therapeutics can be found on EDGAR at www.sec.gov and on SEDAR at www.sedar.com. CASCADIAN THERAPEUTICS, INC.Consolidated Statements of Operations(In thousands except share and per share amounts)(Unaudited)  Three months ended
December 31,Year ended
December 31,  201620152016  2015   Operating Expenses    Research and development$    7,469  $6,887 $   27,467 $23,468 General and administrative    3,121  2,264    17,630  9,321 Intangible asset impairment     â€”  â€”    19,738  â€” Total operating expenses       10,590  9,151     64,835  32,789 Loss from operations   (10,590) (9,151)   (64,835) (32,789)Other income (expense)    Investment and other income (expense), net   78  20    222  80 Change in fair value of warrant liability   —  â€”    —  128 Total other income (expense), net   78  20    222  208 Net loss before income taxes$   (10,512)$(9,131)$   (64,613)$(32,581)Income tax (benefit) provision    â€”  â€”         (6,908) â€” Net loss   (10,512) (9,131)   (57,705) (32,581)Deemed dividend related to beneficial conversion feature on Series D convertible preferred stock    â€”  â€”    (2,588) â€” Net loss attributable to common stockholders   (10,512) (9,131)   (60,293) (32,581)Net loss per share – basic and diluted$   (0.47)$(0.58)$    (3.13)$(2.02)Shares used to compute basic and diluted net loss per share 22,553,642  15,822,410  19,264,121  16,102,860 
 CASCADIAN THERAPEUTICS, INC.Consolidated Balance Sheet Data(In thousands except share amounts)(Unaudited)    As of     December 31, 2016 December 31, 2015  Cash, cash equivalents and investments $  62,805 $  56,360  Total assets  $  83,265 $  96,574  Long term liabilities $  135 $  8,044  Stockholders’ equity $  74,357 $                 83,735  Common shares outstanding  22,562,640  15,826,985 

Investor and Media Contact:
Monique Greer
Cascadian Therapeutics
206-801-2107
[email protected]

Read more...
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Klarman takes 18 percent of cancer treatment developer as FDA fast-tracks product
Seth Klarman (Trades, Portfolio) continues to top weight his portfolio with outsized stakes in health care and pharmaceutical companies. June 30, he bought 18.5% of a company designing a treatment for breast cancer. Read more...
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Company has zero debt and is trading close to a 5-year low
Seth Klarman (Trades, Portfolio) purchased 25 million shares in biotechnology company Cascadian Therapeutics Inc. (NASDAQ:CASC) on June 30. Klarman paid 94 cents per share in a deal that had a 0.34% impact on his portfolio. Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.36
CASC's PB Ratio is ranked higher than
88% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CASC: 1.36 )
Ranked among companies with meaningful PB Ratio only.
CASC' s PB Ratio Range Over the Past 10 Years
Min: 0.74  Med: 3.75 Max: 23.62
Current: 1.36
0.74
23.62
EV-to-EBIT -1.28
CASC's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CASC: -1.28 )
Ranked among companies with meaningful EV-to-EBIT only.
CASC' s EV-to-EBIT Range Over the Past 10 Years
Min: -1611.1  Med: -1.8 Max: 10.1
Current: -1.28
-1611.1
10.1
EV-to-EBITDA -1.29
CASC's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CASC: -1.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
CASC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -8605.4  Med: -1.8 Max: 9.8
Current: -1.29
-8605.4
9.8
Current Ratio 23.75
CASC's Current Ratio is ranked higher than
69% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CASC: 23.75 )
Ranked among companies with meaningful Current Ratio only.
CASC' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 10.53 Max: 36.71
Current: 23.75
1.67
36.71
Quick Ratio 23.75
CASC's Quick Ratio is ranked higher than
70% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CASC: 23.75 )
Ranked among companies with meaningful Quick Ratio only.
CASC' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 10.53 Max: 36.71
Current: 23.75
0.95
36.71

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 2.31
CASC's 5-Year Yield-on-Cost % is ranked higher than
65% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. CASC: 2.31 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
CASC' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.1
Current: 2.31
0
3.1
3-Year Average Share Buyback Ratio -24.20
CASC's 3-Year Average Share Buyback Ratio is ranked lower than
74% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CASC: -24.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CASC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -33  Med: -15.05 Max: -0.3
Current: -24.2
-33
-0.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.71
CASC's Price-to-Net-Cash is ranked higher than
90% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. CASC: 1.71 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CASC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.04  Med: 5.43 Max: 91.28
Current: 1.71
1.04
91.28
Price-to-Net-Current-Asset-Value 1.68
CASC's Price-to-Net-Current-Asset-Value is ranked higher than
90% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. CASC: 1.68 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CASC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.91  Med: 4.89 Max: 36
Current: 1.68
0.91
36
Price-to-Tangible-Book 1.53
CASC's Price-to-Tangible-Book is ranked higher than
85% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CASC: 1.53 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CASC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.84  Med: 4.45 Max: 72.9
Current: 1.53
0.84
72.9
Earnings Yield (Greenblatt) % -78.13
CASC's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CASC: -78.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CASC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 9.9  Med: 148.9 Max: 2633.1
Current: -78.13
9.9
2633.1

More Statistics

EPS (TTM) $ -2.77
Beta2.69
Short Percentage of Float4.39%
52-Week Range $3.49 - 10.98
Shares Outstanding (Mil)49.24

Analyst Estimate

Dec18
Revenue (Mil $)
EPS ($) -0.43
EPS without NRI ($) -0.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CASC

Headlines

Articles On GuruFocus.com
Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for To May 09 2017 
Cascadian Therapeutics to Report First Quarter 2017 Financial Results on May 9, 2017 May 01 2017 
Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Apr 05 2017 
Cascadian Therapeutics Announces Changes to Board of Directors Mar 13 2017 
Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results Mar 09 2017 
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 12 2016 
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics Jul 11 2016 
Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
Cubist Pharmaceutical - Acutely Aware May 09 2010 

More From Other Websites
Edited Transcript of CASC earnings conference call or presentation 9-May-17 12:30pm GMT May 12 2017
Cascadian Therapeutics reports 1Q loss May 09 2017
Investor Network: Cascadian Therapeutics Inc. to Host Earnings Call May 09 2017
Cascadian Therapeutics Reports First Quarter 2017 Financial Results Conference Call Scheduled for... May 09 2017
Cascadian Therapeutics to Report First Quarter 2017 Financial Results on May 9, 2017 May 01 2017
Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for... Apr 05 2017
Cascadian Therapeutics Announces Changes to Board of Directors Mar 13 2017
Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results Mar 09 2017
Cascadian Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference Feb 27 2017
Should You Buy Alico, Inc. (ALCO)? Dec 20 2016
Here’s What Smart Money Think about Jones Energy Inc (JONE) Dec 12 2016
Do Hedge Funds Love Invuity, Inc. (IVTY)? Dec 10 2016
Biotech Movers And Shakers: Cascadian Therapeutics Inc (USA) (CASC) And Anthera Pharmaceuticals Inc... Dec 08 2016
Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards Dec 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)